Kenner JR - Search Results

1

Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype.

Coster TS, Killeen KP, Waldor MK, Beattie DT, Spriggs DR, Kenner JR, Trofa A, Sadoff JC, Mekalanos JJ, Taylor DN. Coster TS, et al. Among authors: kenner jr. Lancet. 1995 Apr 15;345(8955):949-52. doi: 10.1016/s0140-6736(95)90698-3. Lancet. 1995. PMID: 7715293 Clinical Trial.

2

Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1.

Kenner JR, Coster TS, Taylor DN, Trofa AF, Barrera-Oro M, Hyman T, Adams JM, Beattie DT, Killeen KP, Spriggs DR, et al. Kenner JR, et al. J Infect Dis. 1995 Oct;172(4):1126-9. doi: 10.1093/infdis/172.4.1126. J Infect Dis. 1995. PMID: 7561195 Clinical Trial.

3

Development of a live, oral, attenuated vaccine against El Tor cholera.

Taylor DN, Killeen KP, Hack DC, Kenner JR, Coster TS, Beattie DT, Ezzell J, Hyman T, Trofa A, Sjogren MH, et al. Taylor DN, et al. Among authors: kenner jr. J Infect Dis. 1994 Dec;170(6):1518-23. doi: 10.1093/infdis/170.6.1518. J Infect Dis. 1994. PMID: 7995992 Clinical Trial.

4

Nitric oxide production during Vibrio cholerae infection.

Janoff EN, Hayakawa H, Taylor DN, Fasching CE, Kenner JR, Jaimes E, Raij L. Janoff EN, et al. Among authors: kenner jr. Am J Physiol. 1997 Nov;273(5):G1160-7. doi: 10.1152/ajpgi.1997.273.5.G1160. Am J Physiol. 1997. PMID: 9374715

5

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M. Gorse GJ, et al. Vaccine. 2006 Aug 14;24(33-34):5950-9. doi: 10.1016/j.vaccine.2006.05.044. Epub 2006 Jun 5. Vaccine. 2006. PMID: 16797805 Clinical Trial.

6

Response to letter to the editor "Zink TK. Vaccine 2007;25(15):2766-7".

Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M. Gorse GJ, et al. Vaccine. 2007 Oct 16;25(42):7285-7. doi: 10.1016/j.vaccine.2007.08.010. Epub 2007 Aug 27. Vaccine. 2007. PMID: 17850932 No abstract available.

7

LC16m8: an attenuated smallpox vaccine.

Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. Kenner J, et al. Vaccine. 2006 Nov 17;24(47-48):7009-22. doi: 10.1016/j.vaccine.2006.03.087. Epub 2006 Apr 21. Vaccine. 2006. PMID: 17052815 Free PMC article. Review.

8

Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg RN. Kennedy JS, et al. J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15. J Infect Dis. 2011. PMID: 21921208 Free PMC article. Clinical Trial.

9

Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.

Empig C, Kenner JR, Perret-Gentil M, Youree BE, Bell E, Chen A, Gurwith M, Higgins K, Lock M, Rice AD, Schriewer J, Sinangil F, White E, Buller RM, Dermody TS, Isaacs SN, Moyer RW. Empig C, et al. Among authors: kenner jr. Vaccine. 2006 Apr 24;24(17):3686-94. doi: 10.1016/j.vaccine.2005.03.029. Vaccine. 2006. PMID: 16430997

10

Delayed-type hypersensitivity skin testing using third variable loop peptides identifies T lymphocyte epitopes in human immunodeficiency virus-infected persons.

Sitz KV, Loomis-Price LD, Ratto-Kim S, Kenner JR, Sau P, Eckels KH, Redfield RR, Birx DL. Sitz KV, et al. Among authors: kenner jr. J Infect Dis. 1997 Oct;176(4):1085-9. doi: 10.1086/516517. J Infect Dis. 1997. PMID: 9333173

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters